Enara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025
Oxford, United Kingdom – October 3, 2025. Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigen® targets and the development of bispecific T cell engagers for solid tumors, will present two abstracts related to the significant therapeutic potential of DARKFOX™ at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
SITC will take place November 5-9, 2025, in National Harbor, Maryland, USA. Details of Enara’s presentations are as follows:
_______________________________________________________________________________________________________________________________________________________
Discovery and validation of DARKFOX™, a novel alternative open reading frame of FOXM1 that is an attractive cancer antigen for peptide-HLA targeting immunotherapy.
Abstract number: 1298
Oral Presentation: Joe Dukes, Chief Scientific Officer, Enara Bio
Concurrent Session 207c: The Dark Genome: Making Cryptic Epitopes Actionable
Saturday 8th November 3.30-5.10pm ETScheduled presentation time 4.35pm ET
Poster Session: Poster Hall – Saturday 8th November
_______________________________________________________________________________________________________________________________________________________
A novel bispecific T cell engager for the treatment of solid tumors that express DARKFOX™M, a previously undiscovered antigen derived from an alternative open reading frame of FOXM1.
Abstract number: 1163
Poster Session: Poster Hall – Friday 7th November
_______________________________________________________________________________________________________________________________________________________
These presentations will showcase Enara’s newly discovered Dark Antigen, DARKFOX, and the validation of its significant therapeutic potential using a potent bispecific T cell engager, underscoring its promise as a novel target for solid tumor immunotherapy.
Abstract titles are available on the SITC website.
About Enara Bio
Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. Our pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigen® Targets that can address the need for novel, cancer-specific targets in solid tumors. Through our proprietary EnTiCE platform, Enara is developing novel bispecific T cell engagers against Dark Antigen targets that are highly prevalent and homogenously expressed across solid tumors. Our partner, Boehringer Ingelheim, is combining multiple licensed Dark Antigen® Targets to create novel immunotherapies. Based in Oxford, UK, Enara Bio is backed by a strong syndicate of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, SV Health Investors, and the Francis Crick Institute. For more information, visit: www.enarabio.com.
Dark Antigen®, DARKFOXTM and EDAPT® are trademarks of Enara Bio.
Contacts
Kevin Pojasek, President & CEO
info@enarabio.com
Stacey Davis, CBO & CFO
stacey.davis@enarabio.com
Frazer Hall, Mark Swallow
MEDiSTRAVA
enarabio@medistrava.com